Overcome Biochemical Aspirin Resistance Through Cilostazol Combination

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will recruit 316 ischemic stroke patients taking aspirin.

They will be randomly assigned into cilostazol group or placebo group. Every patients will take 200mg of cilostazol a day or placebo for 1 month.

The primary outcome variable of this study is rate of biochemical aspirin resistance on the Ultra Rapid Platelet Function Assay-ASA.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Collaborator: Korea Otsuka Pharmaceutical Co., Ltd.
• Treatments: Aspirin; Cilostazol

Criteria

Inclusion Criteria:

• Symptomatic cerebral infarction documented on MRI or CT

• More than 35 years of age

• Patients taking aspirin 100mg a day for 2 weeks or more before randomization

Exclusion Criteria:

• Patients taking any antiplatelets other than aspirin within 2 weeks before randomization

• Patients taking any anticoagulants within 2 weeks before randomization

• Patients taking thrombolytic therapy within 2 weeks before randomization

• Patients taking any NSAIDs within 2 weeks before randomization

• Patients who need to take NSAIDs regularly (e.g. rheumatic arthritis).

• Bleeding diathesis

• Chronic liver disease (ALT > 100 or AST > 100) or chronic renal disease (creatinine > 3.0mg/dl)

• Anemia (hemoglobin < 10mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3)

• Pregnant or lactating patients

• Patients scheduled for angioplasty or revascularization procedures within 4 weeks

• Patients scheduled for any surgery or invasive procedures within 4 weeks

• Patients having acute coronary syndrome